The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index; 50 of the 105 sources its claims cite were checked for support.
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Open accessAbstract
The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery. However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gut-brain communication can be leveraged to achieve sustained body weight loss without adverse effects.
Overview
CoChat Summary
TL;DR
This review traces the evolution from GLP-1 monoagonists to dual and triple incretin co-agonists as increasingly effective therapies for obesity and diabetes. It argues that the newest triagonists, especially retatrutide, approach bariatric-surgery-level weight loss, but key mechanisms and long-term effects remain unresolved.
Key findings
- Exenatide, the first FDA-approved incretin agonist for diabetes, reduced HbA1c by −0.8% at 5 μg and −1.0% at 10 μg after 30 weeks, and both doses reduced body weight.
- Once-weekly semaglutide 2.4 mg produced −14.9% body-weight reduction in adults with obesity, with improved glucose homeostasis and reduced cardiovascular risk.
- In DIO mice, a balanced GLP-1/glucagon dual agonist produced about 10% greater body-weight reduction than a GLP-1R-favoring version, with similar effects on glucose tolerance.
- Retatrutide showed very large effects: in phase 2 obesity data, 60%, 75%, and 83% of participants on 4, 8, and 12 mg lost at least 15% of body weight by 48 weeks, and the 12 mg dose produced a mean 24.2% weight reduction; in diabetes, 72% of participants with prediabetes returned to normoglycemia vs 22% on placebo.
Methods
- Narrative review of previously published preclinical and clinical studies on incretin monoagonists, dual agonists, and triagonists; no new human or animal experiments were conducted by the authors.
- Synthesizes evidence from DIO mouse studies and human clinical trials, including phase 1, phase 2, and phase 3 studies of agents such as cotadutide, survodutide, mazdutide, tirzepatide, HM15211, and retatrutide.
- Main analysis is qualitative comparison of efficacy, safety/tolerability, and proposed mechanisms across drug classes.
Limitations
- The paper explicitly says that the precise mechanisms driving body-weight reduction remain obscure, especially for the enhanced effects of multiagonism.
- It also states that further research is needed to understand which brain regions, cell types, and downstream circuits mediate incretin effects, and to clarify long-term weight maintenance and lean-mass preservation.
- Evident from the text: this is a review, so its conclusions depend on previously published studies rather than original data collection; the paper says this directly by noting it contains no new studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Synergies in mechanisms that regulate body weight and glucose metabolism by incretin agonism across tissues in humans [22, 23, 106]. Different incretin agonists exert complementary effects on key peripheral organs and the brain to both directly and indirectly affect energy and glucose. GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like protein 1. Created by BioRender.com](https://figures.cochat.ai/paper-figures/6a80cf2b750a4269b1761ba9e6750bdf/dual-and-triple-incretin-based-co-agonists-novel-therapeutics-for-obesity-and-figure-1.jpg)
![Fig. 2 A The amino acid sequence of a GLP-1R/GCGR dual agonist MK1462 [116], B the amino acid sequence of the GLP-1R/GIPR dual agonist tirzepatide [117], and C the amino acid sequence of a triagonist [99]. These multiagonists are an assemblage of parts from each incretin and incorporated lessons learned from prior incretin mimetics: Aib substitute to prevent degradation by DPP4, acylation from liraglutide or semaglutide to increase solubility, and the CEX tail from exendin-4. GCGR glucagon receptor, GIPR GIP receptor, GLP-1R GLP-1 receptor, Aib 2-aminoisobutyric acid, DPP4 dipeptidyl peptidase 4, CEX C-terminal extension](https://figures.cochat.ai/paper-figures/e95e537f71114ac6b6e8937aec699804/dual-and-triple-incretin-based-co-agonists-novel-therapeutics-for-obesity-and-figure-2.jpg)
Verification
Claims the paper makes
34 Valid · 0 Not valid · 35 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite the development, approval and widespread prescription and use of drugs for the treatment of obesity, we have for a long time lacked highly effective anti-obesity drugs [5].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > Introduction
What the sources say
- Supportedcites [5] Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23. source
The Introduction describes drugs approved for obesity treatment and identifies phentermine as commonly prescribed. The History of AOMs says most approaches could not achieve placebo-adjusted mean weight loss greater than 10% at tolerable doses, while noting a recently approved exception, semaglutide 2.4 mg. This supports the claim's historical framing. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, most of these efforts have been plagued with significant adverse effects and/or limited efficacy which has resulted in the withdrawal and discontinued use for the majority of these medications [5].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > Introduction
What the sources say
- Partly supportedcites [5] Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23. sourceExperimental — accuracy not yet measured
The History of AOMs section says many earlier drugs were withdrawn over serious adverse effects and that most approaches struggled to achieve substantial weight loss at tolerable doses. It does not say that a majority of medications were withdrawn or discontinued, and it lists several that remain in use. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“strategies for inhibiting ghrelin signaling have thus far not produced viable pharmacotherapies for obesity, but this is an ongoing area of research [15, 16].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > Introduction
What the sources say
- Supportedcites [15] Hagemann CA, Jensen MS, Holm S, et al. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Rep Med. 2022;3(4):100582. source
The Introduction says that GHSR and ghrelin have been considered therapeutic targets, but that no viable clinical candidate has been developed despite two decades of research. It also describes LEAP2 as a potential future target for obesity, consistent with research being ongoing. (LLM, conf=0.93)
- Supportedcites [16] Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab. 2015;4(6):437–60. source
Section 7.1.2 says ghrelin antagonists were developed as antiobesity drugs but do not appear to have chronic appetite-suppressing effects. Section 7.3 describes continued efforts to block ghrelin action and presents GOAT inhibitors as an opportunity, with weight-loss results in mice rather than an established obesity treatment. Together, these passages support the claim that inhibition had not yet yielded a viable obesity pharmacotherapy and remained under investigation; page numbers were not available in our copy. (LLM, conf=0.86)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Contrary to early loss of function studies that suggested that GIPR drove an increase in body weight, there is no evidence that GIPR agonism increases body weight [85, 86].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > GLP-1/GIP Dual Agonist
What the sources say
- Supportedcites [85] Campbell JE. Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms. Mol Metab. 2021;46:101139. source
Section 3.3 states that no studies reported GIP enhancing weight gain and that the evidence on GIPR agonism does not support the view that it drives weight gain. Section 3.2.2 likewise reports no evidence that chronic GIPR agonism induces weight gain in preclinical models. (LLM, conf=0.94)
- Partly supportedcites [86] Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab. 2019;20:51–62. sourceExperimental — accuracy not yet measured
The Introduction says GIPR mono-agonists do not promote further weight gain in mice with established obesity, and the Results report weight loss with an agonist in diet-induced obese mice. The claim omits that population and treatment context: this paper does not establish that there is no evidence of weight gain from GIPR agonism in any setting. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An optimized GIP agonist, exhibiting full potency for the human GIPR that also acts as an agonist at the mouse GIPR, induced a reduction in body weight and blood glucose in GLP-1R knockout mice but not GIPR knockout mice [46, 86].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > GLP-1/GIP Dual Agonist
What the sources say
- Supportedcites [46] Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(4):833-844.e5. source
The Results section on chronic peripheral acyl-GIP treatment reports reduced body weight in GLP-1R knockout mice but no weight-lowering effect in global Gipr knockout mice (Figure 6; page not provided). The Discussion states that acyl-GIP had no effect on body weight or glycemia in global Gipr knockout mice, while its effects were preserved in GLP-1R knockout mice. (LLM, conf=0.90)
- Supportedcites [86] Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab. 2019;20:51–62. source
The Results sections on in vivo GIPR activity and body-weight lowering report that hGIP Aib2 lowered blood glucose and body weight in Glp1r−/− mice, but not in Gipr−/− mice. The glucose result followed an acute dose; the body-weight result followed chronic treatment of diet-induced obese mice. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
36 more claims · 15 with their cited sources checked
Create a free account to see all 80 claims and every source verdict.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 6
- The quote only partly states this claim. 1
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“This new paradigm began with the discovery of leptin, by Jeff Friedman and others in 1994, the first hormone whose primary function is the regulation of body weight, by signaling from the adipose tissue to pro-opiomelanocortin (POMC) neurons [6] in the hypothalamus to reduce food intake.”
MethodMurray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854 · cited 1×
“The global prevalence of obesity and diabetes continues to surge, contributing significantly to morbidity and mortality through diseases like heart disease and cancer [1].”
BackgroundGhrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×
“This was followed by the discovery of an opposing hormone, ghrelin, which facilitates signaling from the gut and acts on agouti-related peptide (AgRP) neurons in the hypothalamus to increase food intake [7, 8].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Created by BioRender.com liraglutide and semaglutide, but not exenatide, had a lower risk of non-fatal myocardial infarction and stroke [66, 70, 71] and another GLP-1R agonist, dulaglutide, reduced major adverse cardiovascular events [72].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“A once-weekly injection of 2.4 mg of semaglutide resulted in a remarkable reduction in body weight by − 14.9% in adults with obesity, along with substantial improvements in glucose homeostasis and reduced risk of cardiovascular events [66, 67].”
BackgroundInfluentialOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“A once-weekly injection of 2.4 mg of semaglutide resulted in a remarkable reduction in body weight by − 14.9% in adults with obesity, along with substantial improvements in glucose homeostasis and reduced risk of cardiovascular events [66, 67].”
BackgroundInfluentialGenetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534 · cited 1×
“…of leptin has revolved around the idea that BMI has a genetic basis, with approximately 40–70% of the variation in BMI in the population being attributable to heritable factors [9], and that the majority of genetic variation associated with BMI is in the central nervous sys-tem (CNS) [10].”
BackgroundGhrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“This was followed by the discovery of an opposing hormone, ghrelin, which facilitates signaling from the gut and acts on agouti-related peptide (AgRP) neurons in the hypothalamus to increase food intake [7, 8].”
BackgroundSelf-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In its phase 3 trial in adults with obesity, the highest dose of 15 mg once weekly produced an average reduction in body weight of 22.5% after 72 weeks of treatment [91], and a 15.7% reduction in body weight in patients with obesity and diabetes [92].”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“…patients with overweight or obesity and established cardiovascular disease, but no diabetes, that were treated with semaglutide had a significantly lower composite of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) than placebo [73].”
Background
Research works printed but not linked: 2
- IDF Diabetes Atlas 10th edition. International Diabetes Federation; 2021. (IDF Diabetes Atlas). Report no. 10. https://diabetesatlas.org/atlas/tenth-edition/.
- Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691. · DOI · Paper page
Cited by
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 44
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 35
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 28
“…exact mechanisms underlying the weight loss are still not clear, especially in light of the enhanced effects seen with multi-agonism, despite the large number of incretin agonists presently undergoing clinical trials and their remarkable effectiveness in managing obesity and T2DM [5, 14, 146, 147].”
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Metadata
- Authors
- Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D.
- Affiliations
- Helmholtz Munich (DE)
- Universidade de Santiago de Compostela (ES)
- Corresponding author
- Müller, Timo D.
- Venue
- Diabetes Therapy
- Published
- 2024-04-04
- Volume
- 15
- Issue
- 5
- Pages
- 1069-1084
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC11043266
- OpenAlex
- W4393932284
- Semantic Scholar
- 5c836077804f02f246d45c218f15d363cf31e9e6
- Cited by
- 61
- References
- 113
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 6
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- European Research Council (ERC-CoG Trusted no.101044)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- exendin-4, obesity, type 2 diabetes, glucose-dependent insulinotropic polypeptide, GLP-1 receptor, glucagon receptor, weight loss, gut-brain signaling, bariatric surgery alternatives
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. https://app.cochat.ai/papers/10.1007/s13300-024-01566-x
- The paper
- Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024). Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01566-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.